The EHMT1 Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the EHMT1 gene. This product provides a heterogeneous pool of cells harboring targeted disruptions in the EHMT1 locus, generated in the NCI-H1975 lung adenocarcinoma cell line. The polyclonal format captures a range of editing events, enabling robust assessment of EHMT1-dependent phenotypes without clonal selection bias. As a ready-to-use gene knockout model, it supports high-throughput screening and functional validation in a physiologically relevant cancer cell background.
The host cell line, NCI-H1975, is an epithelial cell line derived from a non-small cell lung adenocarcinoma harboring the EGFR T790M gatekeeper mutation. This mutation confers resistance to first-generation EGFR tyrosine kinase inhibitors, making NCI-H1975 a key model for studying acquired drug resistance and tumor progression. The cells retain characteristic lung adenocarcinoma features and are widely employed in epigenetic and signaling studies, offering a clinically relevant context for investigating chromatin-modifying enzymes.
EHMT1 (euchromatic histone lysine methyltransferase 1, also termed G9a-like protein) is a histone methyltransferase that catalyzes mono- and dimethylation of histone H3 at lysine 9 (H3K9me1/2). These marks serve as docking sites for heterochromatin protein 1 (HP1), facilitating chromatin compaction and transcriptional repression. EHMT1 forms heteromeric complexes with EHMT2 (G9a) and interacts with MPP8 and other corepressor components to silence target genes. It operates downstream of regulators such as E2F1, MYC, and p53, and participates in Wnt signaling cascades. Key downstream targets include tumor suppressors CDKN1A (p21) and CDKN2A (p16), as well as HOXA cluster genes, whose repression contributes to cell cycle dysregulation and oncogenic transformation.
In the NCI-H1975 context, EHMT1-mediated H3K9 methylation likely contributes to the silencing of growth-inhibitory genes, fostering unchecked proliferation and drug tolerance. Disruption of EHMT1 in this EGFR-mutant background allows researchers to dissect the interplay between oncogenic kinase signaling and epigenetic silencing. This model is particularly valuable for exploring how EHMT1 cooperates with MYC-driven transcription or attenuates p53 checkpoint responses, and for evaluating whether EHMT1 loss sensitizes cells to EGFR inhibitors or other targeted agents.
Researchers can employ this knockout product to interrogate epigenetic gene regulation, perform functional screens for histone methyltransferase targets, and validate EHMT1 as a therapeutic target in lung adenocarcinoma. Typical assays include western blotting for H3K9me2 and EHMT1, RT-qPCR for derepression of CDKN1A or HOXA genes, ChIP-qPCR to monitor H3K9me2 enrichment at specific promoters, and methyltransferase activity measurements. Moreover, immunofluorescence for heterochromatin foci and proliferation/colony formation assays enable phenotypic assessment of EHMT1 loss. For further details and technical support, please contact Ascent Research.
